Health TrialsbyHealthPanel

Effects of Short-term Intensive Statin Therapy on Lipid Levels

ConditionIschemic Stroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGeneral Hospital of Shenyang Military Region

About this trial

Acute cerebral infarction (ACI), often linked to arterial stenosis, is a major cause of death and disability. Statins are cornerstone therapies for secondary prevention, effectively lowering LDL-C and stabilizing plaques. However, patient response to intensive statin therapy varies significantly. This prospective study aims to analyze the short-term lipid-lowering effects and influencing factors of such therapy in ACI patients with stenosis, to guide personalized treatment and improve outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years;

Diagnosis of ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI; or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%);

Intensive statin therapy (e.g., atorvastatin 40-80 mg/day or rosuvastatin 20 mg/day) initiated within 24 hours of admission, with a planned continuous application for at least one week;

Signed informed consent form.

Disqualifiers

Use of statin therapy within 1 week prior to admission;

Receiving other lipid-lowering treatments;

Presence of other serious comorbidities (e.g., malignant tumors, end-stage heart failure) with an expected survival of <1 year;

Pregnant or lactating women;

Trial population

patients with ischemic stroke (within 14 days of onset) confirmed by cranial CT/MRI, or imaging-confirmed intracranial/extracranial atherosclerotic stenosis (stenosis rate ≥ 50%);

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • statin

    Drug

    Atorvastatin 40-80mg/day, Rosuvastatin 20mg/day

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Absolute reduction in Low-Density Lipoprotein Cholesterol

Time frame
7±1 days

Secondary outcomes

1

Absolute and relative reductions in other lipid parameters (Total Cholesterol, Triglyceride, High-Density Lipoprotein Cholesterol, Lipoprotein a)

Time frame
7±1 days
2

Changes in high-sensitivity C-reactive protein

Time frame
7±1 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

General Hospital of Shenyang Military Region

Lead sponsor

Source ClinicalTrials.gov
Apply now